Alteogen is simultaneously grappling with stock price variables including its decision on bonus shares, remaining on KOSDAQ, and the commercialization performance of 'Hyalozym (ALT-B4),' its subcutaneous injection formulation conversion platform.

In the short term, volatility is expected due to the ex-rights adjustment and an increase in the number of outstanding shares. However, assessments suggest that the company's mid- to long-term value depends on how significantly technology transfer fees and royalty revenues based on ALT-B4 actually expand.

■ Bonus Shares... Approximately 16.19 Million New Shares to Be Issued

Alteogen is pursuing a bonus share issuance, allotting 0.3 new shares per share of both common stock and redeemable convertible preferred stock. Through this bonus share issuance, approximately 16.19 million new shares (combining common and preferred) will be issued, bringing the total number of issued shares to approximately 70.18 million.

A bonus share issuance differs in nature from a paid-in capital increase, which brings new funds into the company. While the number of shares held by shareholders increases, the stock price is theoretically adjusted through an ex-rights adjustment. Therefore, a bonus share issuance alone does not immediately increase corporate value.

The market is closely watching the potential for improved trading accessibility and liquidity following the bonus share issuance. On the other hand, concerns are also being raised that the increase in outstanding shares could expand short-term profit-taking sell-offs.

■ Decision to Remain on KOSDAQ... KOSPI Relisting Temporarily Shelved

Alteogen has decided to temporarily shelve its plan to relist on KOSPI and will remain on the KOSDAQ market. The company explained that this decision was made after comprehensively considering market conditions and KOSDAQ revitalization policies. While the possibility of a relisting has not been completely withdrawn, the company will maintain its supply-demand dynamics and market influence as a major KOSDAQ stock for the time being.

■ The Core is ALT-B4 Commercialization... Global Partnerships with MSD, Sanofi, and Others

At the heart of the company's value lies Hyalozym, a subcutaneous injection formulation conversion platform, and its core substance, ALT-B4. ALT-B4 is a recombinant human hyaluronidase used to convert biopharmaceuticals administered via intravenous injection into subcutaneous injection formulations. Subcutaneous injection formulations can reduce administration time and improve patient convenience compared to traditional intravenous injections, drawing significant interest from global pharmaceutical companies.

The growing demand for formulation conversions, particularly for high-value-added biopharmaceuticals such as anticancer drugs and autoimmune disease treatments, is also positively impacting the value of Alteogen's platform.

A representative commercialized product utilizing ALT-B4 is MSD's subcutaneous injection formulation of Keytruda. The approval and launch of this product have confirmed that ALT-B4 can be applied to actual pharmaceuticals, moving beyond merely being a research-stage technology.

Alteogen is known to have signed ALT-B4-related technology transfer agreements with global pharmaceutical companies, including MSD, Sanofi, AstraZeneca, GSK, Biogen, Daiichi Sankyo, and Intas. The confirmation of Sanofi as the previously undisclosed first technology transfer partner has once again highlighted the expanding scope of the platform business.

■ Patent and Performance Variables... Royalty Inflow is Key

In terms of patents, the process of securing rights related to ALT-B4 is underway in major markets, including the United States and Europe. However, a distinction needs to be made between decisions to grant patents and the actual completion of national registrations. Whether the patent process is finalized and how many subsequent composition and usage patents are secured will serve as benchmarks for assessing future competitiveness.

On the earnings front, the key factors are technology transfer contract fees, milestone payments, service revenues, and the reflection of royalties from commercialized products. For a platform company, revenue volatility can be significant depending not only on individual clinical results but also on partner companies' development speeds, expansion of indications, and actual sales volume.

■ Summary of Short-Term vs. Mid-to-Long-Term Variables

The short-term variables surrounding Alteogen's stock price include the bonus share issuance, ex-rights adjustment, an increase in outstanding shares, and the decision to remain on KOSDAQ. Conversely, mid- to long-term variables include the expansion of Keytruda subcutaneous injection sales, clinical progress of subsequent partner products, additional technology transfers, the scope of patent protection, and actual royalty inflows.

Ultimately, the bonus share issuance is essentially a financial event that increases the share count. The core factor that will determine Alteogen's corporate value lies in how many products utilizing ALT-B4 are approved and sold, and whether technology fees and royalties translate into actual earnings.

[This article was written with the assistance of AI. This article is for reference only for investment decisions and does not recommend buying or selling any specific stock. Investors should verify company disclosures and exchange data before investing.]